Ascendis Pharma Announces New Post Hoc Analysis Showed Substantial Improvement In Observed Estimated Glomerular Filtration Rate, In TransCon PTH-Treated Adults With Hypoparathyroidism
Portfolio Pulse from Happy Mohamed
Ascendis Pharma A/S (NASDAQ:ASND) announced a new post hoc analysis showing that adults with hypoparathyroidism treated with TransCon PTH demonstrated substantial improvement in estimated glomerular filtration rate (eGFR), suggesting improved kidney function. Approximately 50% of Phase 3 PaTHway Trial patients with eGFR < 60 mL/min/1.73m2, the threshold for kidney dysfunction, receiving TransCon PTH experienced eGFR improvement to above 60 mL/min/1.73m2.
September 05, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendis Pharma's TransCon PTH treatment has shown significant improvement in kidney function in adults with hypoparathyroidism. This could potentially lead to increased demand for the treatment and positive impact on the company's stock.
The positive results from the post hoc analysis of Ascendis Pharma's TransCon PTH treatment suggest improved kidney function in adults with hypoparathyroidism. This could potentially lead to increased demand for the treatment, which would likely have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100